Implantation failure occurs when an embryo does not successfully attach to the uterine lining and establish a pregnancy. In natural conception, this happens more often than most people realize, since many fertilized eggs fail to implant without a woman ever knowing conception occurred. In the context of fertility treatment, the term takes on a more specific clinical meaning: embryos are transferred directly into the uterus, and when pregnancy doesn’t result, the failure point is clearly at implantation. Roughly 10% of couples undergoing IVF experience this repeatedly.
When Implantation Happens
Implantation typically occurs about 9 days after ovulation, though it can range from 6 to 12 days. The uterine lining is only receptive to an embryo during a narrow window lasting 2 to 3 days. During this window, tiny balloon-like structures form on the surface of the uterine lining. These structures are fully developed for just 1 to 2 days, and they help the embryo make initial contact by pushing past the protective mucus layer that normally coats the lining. If the embryo arrives too early or too late relative to this window, it simply cannot attach.
What Counts as Recurrent Implantation Failure
A single failed embryo transfer is common and not necessarily a sign of an underlying problem. Clinicians reserve the diagnosis of recurrent implantation failure (RIF) for a pattern of repeated failures. The most widely accepted definition comes from Coughlan: no clinical pregnancy after transferring at least four good-quality embryos across a minimum of three fresh or frozen cycles in a woman under 40. The European Society of Human Reproduction and Embryology uses a slightly different threshold, defining RIF as failure after transferring more than three good-quality embryos or ten embryos across multiple cycles. In practice, an international survey found that most clinicians and embryologists diagnose RIF after three failed cycles, regardless of the exact embryo count.
Embryo Quality and Chromosomal Problems
The single largest reason embryos fail to implant is that they carry the wrong number of chromosomes, a condition called aneuploidy. These embryos may look perfectly normal under a microscope but are genetically unable to develop. The rate of chromosomal abnormality rises sharply with age. In women under 35, about 55% of embryos tested carry abnormal chromosomes. That number climbs to roughly 68% in women aged 38 to 40, and reaches nearly 73% in women over 40. Only about 17% of embryos from women over 40 are chromosomally normal, compared to 37% in women under 35.
When genetically normal embryos are selected and transferred, the implantation rate is around 40% and the miscarriage rate drops to essentially zero in some studies. This is why preimplantation genetic testing has become a central tool in addressing implantation failure, particularly for women in their late 30s and beyond.
Uterine Lining Problems
Even a chromosomally normal embryo needs a healthy uterine environment to implant. One of the most underdiagnosed conditions is chronic endometritis, a low-grade infection of the uterine lining caused by bacteria. Unlike acute infections, chronic endometritis rarely causes obvious symptoms. Some women notice irregular bleeding or mild pelvic discomfort, but many have no symptoms at all. It affects an estimated 10 to 30% of women with infertility, and the prevalence jumps to as high as 60% in women with recurrent implantation failure or recurrent pregnancy loss. Because standard fertility workups often miss it, some cases of “unexplained” infertility may trace back to this treatable condition.
Uterine fibroids also play a role, though the type matters enormously. Submucosal fibroids, which grow into the uterine cavity, reduce implantation rates to around 4.3%, compared to 15.7% in women without fibroids. Intramural fibroids, which sit within the uterine wall, also lower implantation rates to about 6.4%, even when they don’t visibly distort the cavity. Subserosal fibroids, which grow on the outer surface of the uterus, do not appear to affect implantation at all, with rates nearly identical to women without fibroids.
Immune System Imbalances
The uterine lining contains specialized immune cells called uterine natural killer cells, which play a counterintuitive role: despite their name, they normally help implantation succeed by guiding the embryo’s invasion into the lining and remodeling blood vessels to supply the early pregnancy. Problems arise when the immune environment shifts toward an inflammatory state. In that scenario, these cells can transform into aggressive versions that target the embryo rather than support it. Other immune cells follow suit, creating a hostile environment. Research on women with recurrent implantation failure has found significantly higher counts of these immune cells, correlated with faulty blood vessel development in the lining, a process essential for the embryo to establish a blood supply.
Sperm DNA Damage
Implantation failure is not always a female-factor issue. Damage to sperm DNA, measured by a metric called the DNA fragmentation index (DFI), can prevent normal embryo development after fertilization even when the sperm looks healthy under a microscope. A DFI under 15% is considered normal, while values above 30% indicate poor DNA integrity. Men with elevated fragmentation don’t necessarily see lower fertilization rates, but miscarriage rates rise significantly. In IVF and ICSI cycles, men with a DFI above 30% have substantially higher miscarriage rates than those below 15%, with a clear dose-response relationship: each percentage point increase in fragmentation correlates with roughly 10% higher odds of miscarriage.
Body Weight and Implantation
Obesity has a measurable negative effect on implantation. A large Chinese study of over 22,000 frozen embryo transfer cycles found that obese women had 20% lower odds of implantation compared to normal-weight women, after adjusting for other factors. This effect operates through multiple pathways, including altered hormone levels, increased inflammation in the uterine lining, and changes to the metabolic environment the embryo encounters during its first days of contact with the uterus.
Diagnostic Testing and Its Limits
One test that has generated significant attention is the endometrial receptivity analysis (ERA), which aims to identify whether a woman’s implantation window is shifted and then time the embryo transfer accordingly. The concept is appealing, but the evidence is mixed. In one study, the proportion of women whose test came back as “non-receptive” was essentially the same whether they had a history of failed transfers (40 to 45%) or no such history (52%). More importantly, women with three or more prior failed transfers who followed the test’s personalized timing recommendations still had significantly lower live birth rates (28%) compared to controls (54%). Even among women with non-receptive results who adjusted their transfer timing, the live birth rate was just 13% for those with recurrent failures, versus 51% for controls. The test did not reliably distinguish between women with and without implantation problems, suggesting that the causes of failure in most cases lie elsewhere.
Transfer Media and Adherence Compounds
A more straightforward intervention involves the medium used to transfer the embryo into the uterus. Transfer media enriched with hyaluronic acid, sometimes marketed as “embryo glue,” creates a viscous environment that may help the embryo stay in contact with the uterine lining. In a study comparing outcomes, the clinical pregnancy rate was 69.5% with embryo glue versus 57.6% with standard media. The benefit was present across age groups but was particularly pronounced in women 35 and older, where the pregnancy rate jumped from 44.6% to 63.6%.
Blood Clotting Disorders
Inherited blood clotting disorders (thrombophilias) have been proposed as a cause of implantation failure, with the theory being that tiny clots in the blood vessels of the uterine lining could starve the implanting embryo of oxygen. Women with certain antibodies (antiphospholipid antibodies) do appear to have worse outcomes and are sometimes treated with blood thinners. However, for the more common inherited clotting mutations, the evidence does not support a connection. A study comparing women who failed IVF to controls found no significant difference in the prevalence of the most common thrombophilia mutations. The conclusion: routine anticoagulant treatment for women undergoing IVF is not warranted based on current evidence, unless specific antibody testing indicates otherwise.